These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 16077916

  • 1. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
    Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S.
    Int J Oncol; 2005 Sep; 27(3):681-5. PubMed ID: 16077916
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
    Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y.
    Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
    [Abstract] [Full Text] [Related]

  • 3. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
    Barok M, Tanner M, Köninki K, Isola J.
    Cancer Lett; 2011 Jul 28; 306(2):171-9. PubMed ID: 21458915
    [Abstract] [Full Text] [Related]

  • 4. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.
    Cancer Sci; 2012 Feb 28; 103(2):342-9. PubMed ID: 22050138
    [Abstract] [Full Text] [Related]

  • 5. Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts.
    Yamamoto Y, Yoshida M, Sato M, Sato K, Kikuchi S, Sugishita H, Kuwabara J, Matsuno Y, Kojima Y, Morimoto M, Horiuchi A, Watanabe Y.
    Int J Oncol; 2011 Jan 28; 38(1):33-9. PubMed ID: 21109923
    [Abstract] [Full Text] [Related]

  • 6. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS.
    Clin Cancer Res; 2010 Mar 01; 16(5):1509-19. PubMed ID: 20179222
    [Abstract] [Full Text] [Related]

  • 7. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
    Ninomiya S, Inomata M, Tajima M, Ali AT, Ueda Y, Shiraishi N, Kitano S.
    J Surg Res; 2009 Jun 15; 154(2):196-202. PubMed ID: 19329124
    [Abstract] [Full Text] [Related]

  • 8. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
    Hamano S, Mori Y, Aoyama M, Kataoka H, Tanaka M, Ebi M, Kubota E, Mizoshita T, Tanida S, Johnston RN, Asai K, Joh T.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):846-54. PubMed ID: 25444894
    [Abstract] [Full Text] [Related]

  • 9. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ, Kang X.
    Int J Oncol; 2009 Jan 28; 34(1):25-32. PubMed ID: 19082474
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
    Saeki H, Yanoma S, Takemiya S, Sugimasa Y, Akaike M, Yukawa N, Rino Y, Imada T.
    Oncol Rep; 2007 Aug 28; 18(2):433-9. PubMed ID: 17611667
    [Abstract] [Full Text] [Related]

  • 11. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin.
    Shinohara H, Morita S, Kawai M, Miyamoto A, Sonoda T, Pastan I, Tanigawa N.
    J Surg Res; 2002 Feb 28; 102(2):169-77. PubMed ID: 11796015
    [Abstract] [Full Text] [Related]

  • 12. Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein.
    Zhang DX, Zhao PT, Xia L, Liu LL, Liang J, Zhai HH, Zhang HB, Guo XG, Wu KC, Xu YM, Jia LT, Yang AG, Chen SY, Fan DM.
    Gut; 2010 Mar 28; 59(3):292-9. PubMed ID: 19951902
    [Abstract] [Full Text] [Related]

  • 13. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
    Kasuya K, Shimazu M, Suzuki M, Itoi T, Aoki T, Tsuchida A.
    Int J Mol Med; 2010 Feb 28; 25(2):209-15. PubMed ID: 20043129
    [Abstract] [Full Text] [Related]

  • 14. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y, Shu S, Harada N, Fujimoto-Ouchi K.
    Oncol Rep; 2013 Sep 28; 30(3):1087-93. PubMed ID: 23783223
    [Abstract] [Full Text] [Related]

  • 15. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.
    Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K.
    Clin Cancer Res; 2011 Aug 01; 17(15):5060-70. PubMed ID: 21700765
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.
    Tomioka H, Mukohara T, Kataoka Y, Ekyalongo RC, Funakoshi Y, Imai Y, Kiyota N, Fujiwara Y, Minami H.
    Int J Oncol; 2012 Aug 01; 41(2):551-8. PubMed ID: 22614071
    [Abstract] [Full Text] [Related]

  • 17. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
    Gong SJ, Jin CJ, Rha SY, Chung HC.
    Cancer Lett; 2004 Oct 28; 214(2):215-24. PubMed ID: 15363548
    [Abstract] [Full Text] [Related]

  • 18. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
    Luistro LL, Rosinski JA, Bian H, Bishayee S, Rameshwar P, Ponzio NM, Ritland SR.
    Int J Oncol; 2012 Aug 28; 41(2):639-51. PubMed ID: 22580986
    [Abstract] [Full Text] [Related]

  • 19. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
    Zhou XX, Ji F, Zhao JL, Cheng LF, Xu CF.
    J Gastroenterol Hepatol; 2010 Jul 28; 25(7):1266-75. PubMed ID: 20594254
    [Abstract] [Full Text] [Related]

  • 20. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA.
    Semin Oncol; 1999 Aug 28; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.